Tumor Suppressor Proteins
"Tumor Suppressor Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
| Descriptor ID |
D025521
|
| MeSH Number(s) |
D12.776.624.776
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Proteins".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Proteins".
This graph shows the total number of publications written about "Tumor Suppressor Proteins" by people in this website by year, and whether "Tumor Suppressor Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 1999 | 5 | 0 | 5 |
| 2000 | 3 | 1 | 4 |
| 2001 | 3 | 4 | 7 |
| 2002 | 3 | 14 | 17 |
| 2003 | 6 | 9 | 15 |
| 2004 | 2 | 12 | 14 |
| 2005 | 8 | 7 | 15 |
| 2006 | 7 | 3 | 10 |
| 2007 | 12 | 15 | 27 |
| 2008 | 8 | 4 | 12 |
| 2009 | 7 | 5 | 12 |
| 2010 | 16 | 9 | 25 |
| 2011 | 8 | 5 | 13 |
| 2012 | 11 | 10 | 21 |
| 2013 | 12 | 7 | 19 |
| 2014 | 7 | 5 | 12 |
| 2015 | 6 | 10 | 16 |
| 2016 | 7 | 4 | 11 |
| 2017 | 8 | 7 | 15 |
| 2018 | 5 | 6 | 11 |
| 2019 | 7 | 6 | 13 |
| 2020 | 6 | 6 | 12 |
| 2021 | 4 | 6 | 10 |
| 2022 | 2 | 6 | 8 |
| 2023 | 1 | 5 | 6 |
| 2024 | 1 | 3 | 4 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Proteins" by people in Profiles.
-
Folliculin Deletion in the Mouse Kidney Results in Cystogenesis of the Loops of Henle via Aberrant TFEB Activation. Am J Pathol. 2025 Sep; 195(9):1643-1659.
-
Folliculin depletion results in liver cell damage and cholangiocarcinoma through MiT/TFE activation. Cell Death Differ. 2025 Aug; 32(8):1460-1472.
-
MGMT epimutations and risk of incident cancer of the colon, glioblastoma multiforme, and diffuse large B cell lymphomas. Clin Epigenetics. 2025 Feb 20; 17(1):28.
-
DNA-binding affinity and specificity determine the phenotypic diversity in BCL11B-related disorders. Am J Hum Genet. 2025 Feb 06; 112(2):394-413.
-
Association of common and rare variants with Alzheimer's disease in more than 13,000 diverse individuals with whole-genome sequencing from the Alzheimer's Disease Sequencing Project. Alzheimers Dement. 2024 Dec; 20(12):8470-8483.
-
Analysis of DNA Methylation in Gliomas: Assessment of Preanalytical Variables. Lab Invest. 2024 12; 104(12):102160.
-
COMPREHENSIVE MOLECULAR PROFILING OF UVEAL MELANOMA EVALUATED WITH GENE EXPRESSION PROFILING, PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA EXPRESSION, AND NEXT-GENERATION SEQUENCING. Retina. 2024 09 01; 44(9):1580-1589.
-
GZ17-6.02 kills PDX isolates of uveal melanoma. Oncotarget. 2024 May 17; 15:328-344.
-
The genomic landscape of familial glioma. Sci Adv. 2023 04 28; 9(17):eade2675.
-
Disease-related p63 DBD mutations impair DNA binding by distinct mechanisms and varying degree. Cell Death Dis. 2023 04 18; 14(4):274.